文献速递胸部肿瘤支持与姑息治疗

化疗与癌症患者COVID-19结局的关系

Chemotherapy and COVID-19 Outcomes in Patients With Cancer.
PubMed 文献 · J Clin Oncol · 2020-08-14

该研究回顾了309例在Memorial Sloan Kettering癌症中心合并COVID-19的癌症患者,发现近期细胞毒性化疗与严重或危重COVID-19事件无显著关联(HR 1.10),但血液系统恶性肿瘤、肺癌、淋巴细胞减少及基线中性粒细胞减少与更差结局相关。

要点

  • 近期细胞毒性化疗未显著增加严重或危重COVID-19风险。
  • 血液系统恶性肿瘤和肺癌患者COVID-19严重程度更高。
  • 诊断时淋巴细胞减少及基线中性粒细胞减少提示预后更差。

核心结论

  • 近期细胞毒性化疗与不良COVID-19结局无关。
  • 活动性血液系统或肺部恶性肿瘤、围COVID-19期淋巴细胞减少或基线中性粒细胞减少的患者COVID-19结局更差。

研究设计与样本

  • 回顾性队列研究,纳入2020年3月31日前在Memorial Sloan Kettering癌症中心合并COVID-19的癌症患者309例,观察至2020年4月13日。

主要发现

  • 细胞毒性化疗给药与严重或危重COVID-19事件无显著关联(HR 1.10;95% CI 0.73-1.60)。
  • 血液系统恶性肿瘤与COVID-19严重程度增加相关(HR 1.90;95% CI 1.30-2.80)。
  • 肺癌患者严重或危重COVID-19事件发生率更高(HR 2.0;95% CI 1.20-3.30)。
  • COVID-19诊断时淋巴细胞减少与更高的严重或危重疾病发生率相关(HR 2.10;95% CI 1.50-3.10)。
  • COVID-19诊断前14-90天基线中性粒细胞减少的患者结局更差(HR 4.20;95% CI 1.70-11.00)。

临床怎么用

  • 对于近期接受细胞毒性化疗的癌症患者,不应仅因化疗史而过度担忧COVID-19不良结局。
  • 应关注血液系统恶性肿瘤、肺癌、淋巴细胞减少及基线中性粒细胞减少的患者,因其COVID-19不良结局风险更高。

局限性

  • 研究为单中心回顾性分析,样本量有限,可能存在未测量的混杂因素。
  • 抗肿瘤治疗、癌症类型与COVID-19之间的交互作用复杂,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Coronavirus-2019 (COVID-19) mortality is higher in patients with cancer than in the general population, yet the cancer-associated risk factors for COVID-19 adverse outcomes are not fully characterized. PATIENTS AND METHODS: We reviewed clinical characteristics and outcomes from patients with cancer and concurrent COVID-19 at Memorial Sloan Kettering Cancer Center until March 31, 2020 (n = 309), and observed clinical end points until April 13, 2020. We hypothesized that cytotoxic chemotherapy administered within 35 days of a COVID-19 diagnosis is associated with an increased hazard ratio (HR) of severe or critical COVID-19. In secondary analyses, we estimated associations between specific clinical and laboratory variables and the incidence of a severe or critical COVID-19 event. RESULTS: Cytotoxic chemotherapy administration was not significantly associated with a severe or critical COVID-19 event (HR, 1.10; 95% CI, 0.73 to 1.60). Hematologic malignancy was associated with increased COVID-19 severity (HR, 1.90; 95% CI, 1.30 to 2.80). Patients with lung cancer also demonstrated higher rates of severe or critical COVID-19 events (HR, 2.0; 95% CI, 1.20 to 3.30). Lymphopenia at COVID-19 diagnosis was associated with higher rates of severe or critical illness (HR, 2.10; 95% CI, 1.50 to 3.10). Patients with baseline neutropenia 14-90 days before COVID-19 diagnosis had worse outcomes (HR, 4.20; 95% CI, 1.70 to 11.00). Findings from these analyses remained consistent in a multivariable model and in multiple sensitivity analyses. The rate of adverse events was lower in a time-matched population of patients with cancer without COVID-19. CONCLUSION: Recent cytotoxic chemotherapy treatment was not associated with adverse COVID-19 outcomes. Patients with active hematologic or lung malignancies, peri-COVID-19 lymphopenia, or baseline neutropenia had worse COVID-19 outcomes. Interactions among antineoplastic therapy, cancer type, and COVID-19 are complex and warrant further investigation.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Jee J, Foote MB, Lumish M, et al. Chemotherapy and COVID-19 Outcomes in Patients With Cancer. J Clin Oncol. 2020. PMID: 32795225. doi:10.1200/JCO.20.01307

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。